ALX Oncology Gets Orphan Drug Designation for Leukemia Treatment

  ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation (“ODD”) to evorpacept, a next-generation CD47 blocker, for the treatment of patients with acute myeloid leukemia (“AML”).

https://finance.yahoo.com/news/alx-oncology-receives-u-fda-110000648.html